"In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients," said John Rim, President and CEO of Samsung Biologics. "With full operations in plants at our Bio Campus I and Plant 5 ramp-up underway, we are further strengthening manufacturing readiness and service capacity to support evolving client needs. As our global footprint continues to expand, we remain focused on quality excellence, operational consistency, and strategic investment to support sustainable long-term growth."

• Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion
• Performance driven by full utilization across Plants 1 through 4 and robust operational execution
• Strengthened the foundations for future growth through U.S. expansion and strategic partnerships

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.

Financial Highlights

In the first quarter of 2026, Samsung Biologics reported revenue of KRW 1,257 billion and operating profit of KRW 581 billion. Performance was mainly driven by full utilization across Plants 1 through 4 and continued project execution.

Samsung Biologics maintained solid momentum, with cumulative contract value exceeding USD 21.4 billion, reflecting continued demand from global clients. The company successfully completed the first commercial-scale engineering run at its dedicated antibody-drug conjugate facility, demonstrating operational readiness and execution capabilities across diverse modalities.

Business Updates and 2026 Outlook

Samsung Biologics remains on track to meet its 2026 guidance, supported by continued operations across Plants 1 through 4 and the progressive ramp-up of Plant 5.

In March, Samsung Biologics completed the acquisition of its Rockville manufacturing facility in Maryland, U.S. for USD 353 million, establishing its first U.S. manufacturing presence and further strengthening client proximity and supply chain resilience in a key market. Samsung Biologics also continues to evaluate strategic investments to further diversify its manufacturing network and support clients seeking regional supply alignment amid an evolving global operating environment.

Samsung Biologics entered a strategic partnership with Coalition for Epidemic Preparedness Innovations (CEPI) to support global health emergency preparedness through agile manufacturing capacity and rapid response capabilities. In addition, the company announced a collaboration with Eli Lilly and Company to foster open innovation and biotechnology ecosystem development. These initiatives reflect the company's broader commitment to long-term industry collaboration and sustainable growth.

The company continued to strengthen its integrated service offering through expanded CDO capabilities, including master cell bank production and vector construction services, supporting broader development solutions for clients. Cumulative regulatory approvals surpassed 440, reflecting Samsung Biologics' continued focus on quality, compliance, and reliable execution across global markets.

On the sustainability front, Samsung Biologics achieved the EcoVadis' Platinum rating, the highest level of recognition for corporate sustainability performance. The company also completed third-party validation of its Product Carbon Footprint system and published its ESG engagement report to strengthen transparency and stakeholder collaboration. At this year's CDMO Leadership Awards, Samsung Biologics was awarded the Sustainability Leadership Award, a jury-selected distinction recognizing efforts to advance sustainable practices across its operations and value chain.